Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 15/20 | 0.59 |
| ▸ | PIK3C2B | O00750 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL716728 | 0.91 | PIK3CD (0.57) | PIK3CDPIK3C2B | |
| SCHEMBL715578 | 0.82 | PIK3CD (0.47) | PIK3CDPIK3C2B | |
| SCHEMBL17530763 | 0.81 | KDM4E (0.40) | PIK3CDPIK3C2BKDM4EMEN1KMT2A | |
| SCHEMBL716170 | 0.76 | PIK3CD (0.58) | PIK3CDPIK3C2BKDM4EMEN1KMT2A | |
| SCHEMBL15864430 | 0.75 | PIK3CD (0.56) | PIK3CDPIK3C2BKDM4EMEN1KMT2A | |
| SCHEMBL788414 | 0.74 | PIK3CD (1.00) | PIK3CDPIK3C2B | |
| SCHEMBL1880927 | 0.74 | PIK3CD (0.41) | PIK3CD | |
| SCHEMBL15864240 | 0.73 | PIK3CD (0.54) | PIK3CDPIK3C2BKDM4EMEN1KMT2A | |
| SCHEMBL15864600 | 0.72 | PIK3CD (0.49) | PIK3CDPIK3C2BKDM4EMEN1KMT2A | |
| SCHEMBL17530775 | 0.71 | MAPT (0.40) | PIK3CDPIK3C2BKDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2403847-B1 | TRIAZINE DERIVATIVES AS KINASE INHIBITORS | UCB BIOPHARMA SPRL (BE) | 2016-03-02 | — | — | EP | claimed |
| US-8785628-B2 | Triazine derivatives as kinase inhibitors | UCB PHARMA, S.A. (BE) | 2014-07-22 | — | — | US | claimed |
| EP-2403847-B1 | TRIAZINE DERIVATIVES AS KINASE INHIBITORS | UCB BIOPHARMA SPRL (BE) | 2016-03-02 | — | — | EP | disclosed |
| US-8785628-B2 | Triazine derivatives as kinase inhibitors | UCB PHARMA, S.A. (BE) | 2014-07-22 | — | — | US | disclosed |
| US-20120053167-A1 | Triazine Derivatives as Kinase Inhibitors | UCB PHARMA, S.A. (BE) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053167-A1 | Triazine Derivatives as Kinase Inhibitors | MAP3K15, PI4KA, MAP3K20 | PIK3CD 12/4885PIK3C2B 69/4885KDM4E 2430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.